Lava Therapeutics

Lava is a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies.

Lava's mission is to develop potent, safe and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells.

Lava was founded in 2016 by Erik van den Berg and Hans van der Vliet. The company is headquartered in Utrecht, Utrecht, Netherlands.

 

Lava's first-in-class immuno-oncology approach activates γδ T cells in a tumor target dependent manner. The company’s proprietary γδ TCR-bispecific antibody platform originates from cutting-edge research at the VU University Medical Center and Cancer Center Amsterdam. 

 

LAVA’s bispecific gamma-delta T cell engager platform is harnessing the unique properties of these T cells creating a revolutionary truly tumor-targeted immunotherapy to improve outcomes for cancer patients.

 

Lava is backed by Versant Ventures, Gilde Healthcare, Merck Research Labs Ventures, Novo Ventures, RL Ventures Fund, Redmile Group, LLC, Ysios Capital and others. The company raised $83M in Series C round on Sep 17, 2020. This brings Lava's total funding $102.9M to date.

 

 

  • Year founded: 2016
  • Funding Info: $102.9M over 4 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Utrecht
  • State: Utrecht
  • Country: Netherlands
Related businesses